PGC-1α基因多态性与代谢性疾病的相关性

doi:10.12092/j.issn.1009-2501.2019.10.014

中国临床药理学与治疗学 ›› 2019, Vol. 24 ›› Issue (10): 1172-1180.doi: 10.12092/j.issn.1009-2501.2019.10.014

PGC-1α基因多态性与代谢性疾病的相关性

范志鹏¹，李玲^1,2，赵慧佳¹，陈彬尧¹，刘晓红¹，郝卓文¹，孙功鹏¹，董礼¹，乐江²，吴建国³，叶啟发^1,4

¹武汉大学中南医院，武汉大学肝胆疾病研究院，武汉大学移植医学中心，移植医学技术湖北省重点实验室，²武汉大学基础医学院药理教研室， ³武汉大学生命科学学院，病毒学国家重点实验室，武汉 430071，湖北； ⁴中南大学湘雅三医院，卫生部移植医学工程技术研究中心，长沙 410013，湖南

收稿日期:2018-09-21 修回日期:2019-09-05 出版日期:2019-10-26 发布日期:2019-10-28
通讯作者: 叶啟发，男，教授，主任医师，研究方向：肝胆外科，器官移植。 Tel: 027-67812988 E-mail: yqf_china@163.com
作者简介:范志鹏，男，本科，研究方向：器官移植术后并发症的个体化治疗。 Tel:18296669769 E-mail:1217379931@qq.com 李玲，女，共同第一作者，博士研究生在读，主管药师，研究方向：器官移植术后并发症的个体化治疗。 Tel:15387041070 E-mail: wh001019@whu.edu.cn
基金资助:
2016年湖北省技术创新专项（2016ACA155）；病毒学国家重点实验室开放研究基金资助项目（2018KF005）；湖北省卫计委药护技和管理专项（WJ2017H0024）

Correlation between PGC-1α gene polymorphism and metabolic diseases

FAN Zhipeng¹, LI Ling ^1,2, ZHAO Huijia ¹, CHEN Binyao ¹, LIU Xiaohong¹, HAO Zhuowen ¹, SUN Gongpeng ¹, DONG Li ¹, YUE Jiang², WU Jianguo³, YE Qifa ^1,4

¹ Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases of Wuhan University, Transplant Center of Wuhan University, Hubei Key Laboratory of Medical Technology on Transplantation；² Department of Pharmacology, Basic Medical School of Wuhan University; ³ College of Life Sciences of Wuhan University, State Key Laboratory of Virology, Wuhan 430071，Hubei, China；⁴The 3rd Xiangya Hospital of Central South University, Research Center of National Health Ministry on Transplantation Medicine Engineering and Technology, Changsha 410013，Hunan，China

Received:2018-09-21 Revised:2019-09-05 Online:2019-10-26 Published:2019-10-28

摘要/Abstract

摘要：

过氧化物酶体增殖物激活受体γ共激活因子1-α（peroxisome proliferator-activated receptor gamma coactivator 1-alpha,PGC-1α）属于人体内一种重要的核转录辅助激活因子，能与多种核受体及转录因子相互作用，以调控其靶基因的表达。PGC1-α在人体能量代谢中发挥着重要的作用，其参与脂肪酸氧化，肝糖异生以及调节线粒体ATP的生物合成等。研究表明PGC-1α基因多态性与Ⅱ型糖尿病、糖尿病肾病、肥胖以及冠心病等代谢性疾病的发生有着密切的关系。探究PGC-1α基因多态性与代谢性疾病的相关性有利于从基因层面检测和评估代谢类疾病的发生风险，从而实现早期发现和预防该疾病的发生，提高代谢性疾病的生存质量，延长生存期。本文拟就近五年PGC-1α参与的代谢途径和其基因多态性与代谢性疾病的相关性的研究进展做一综述。

关键词: 过氧化物酶体增殖物激活受体γ共激活因子1-α, 代谢性疾病, 基因多态性

Abstract:

Peroxisome proliferator-activated receptor gamma coactivator 1-alpha（PGC-1α）is an important nuclear transcriptional coactivator in human body. Nuclear receptors and transcription factors interact to regulate the expression of their target genes. PGC1-α plays an important role in human energy metabolism, which is involved in fatty acid oxidation, hepatic gluconeogenesis and regulation of mitochondrial ATP biosynthesis.Studies have shown that PGC-1α gene polymorphism is closely related to the occurrence of metabolic diseases such as type 2 diabetes, diabetic nephropathy, obesity and coronary heart disease. Exploring the correlation between PGC-1α gene polymorphism and metabolic diseases is beneficial to detect and evaluate the risk of metabolic diseases from the genetic level, so as to realize early detection and prevention of the disease, improve the quality of life of metabolic diseases, and prolong Survival period. This article reviews the research progress of the metabolic pathways involved in PGC-1α and the correlation between its genetic polymorphisms and metabolic diseases in the recent five years.

Key words: peroxisome proliferator-activated receptor gamma coactivator 1-alpha, metabolism, gene polymorphism

中图分类号:

R968
R589

范志鹏，李玲，赵慧佳，陈彬尧，刘晓红，郝卓文，孙功鹏，董礼，乐江，吴建国，叶啟发. PGC-1α基因多态性与代谢性疾病的相关性[J]. 中国临床药理学与治疗学, 2019, 24(10): 1172-1180.

FAN Zhipeng, LI Ling, ZHAO Huijia, CHEN Binyao, LIU Xiaohong, HAO Zhuowen, SUN Gongpeng, DONG Li, YUE Jiang, WU Jianguo, YE Qifa. Correlation between PGC-1α gene polymorphism and metabolic diseases[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1172-1180.

参考文献

［1］ Wang X, Wen F, Hong T, et al. The research progress of peroxisome proliferator activated receptor γ coactivator 1α［J］. Int J Pathol Clin Med, 2012, 32(1):45-49.
［2］Handschin C, Spiegelman BM.Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators energy homeostasis and metabolis［J］. Endocrinol Rev, 2006, 27(7):728-735.
［3］Liu C, Lin JD.PGC-1 coactivators in the control of energy metabolism［J］. Acta Biochim Biophys Sin (Shanghai), 2011, 43(4):248-257.
［4］闫春雷，黄欣，苏乐群，等. PGC-1α的转录调节和翻译后修饰［J］. 中国生物化学与分子生物学报，2015，1（1）：12-19.
［5］Lee J, Salazar Hernández MA, Auen T, et al. PGC-1α functions as a co-suppressor of XBP1s to regulate glucose metabolism ［J］. Mol Metab, 2018, 7:119-131.
［6］Tavares CD, Sharabi K, Dominy JE, et al. The methionine transamination pathway controls hepatic glucose metabolism through regulation of the GCN5 acetyltransferase and the PGC-1αtranscriptional coactivator［J］. J Biol Chem, 2016, 291(20):10635-10645.
［7］Hatazawa Y, Qian K. PGC-1α regulates alanine metabolism in muscle cells［J］. PLoS One, 2018, 13(1): e0190904.
［8］Yao L, Cui X, Chen Q, et al. Cold-Inducible SIRT6 regulates thermogenesis of brown and beige fat［J］. Cell Rep, 2017, 20(3): 641-654.
［9］Crisol BM, Veiga CB, Lenhare L, et al.Nicotinamide riboside induces a thermogenic response in lean mice［J］. Life Sci, 2018, 211:1-7.
［10］Zhang X, Zhang QX, Wang X, et al. Dietary luteolin activates browning and thermogenesis in mice through an AMPK/PGC-1αpathway-mediated mechanism［J］.Int J Obes (Lond), 2016, 40(12): 1841-1849.
［11］Gill JA, La Merrill MA.An emerging role for epigenetic regulation of PGC-1α expression in environmentally stimulated brown adipose thermogenesis［J］. Environ Epigenet, 2017, 3(2): dvx009.
［12］Villena JA. New insights into PGC-1 coactivators: redefining their role in the regulation of mitochondrial function and beyond［J］. FEBS J, 2015, 282(4): 647-672.
［13］Fang He, Jie-Qiong Jin, Qing-Qing Qin, et al.Resistin regulates fatty acid β oxidation by suppressing expression of peroxisome proliferator activator receptor gamma-coactivator 1α (PGC-1α)［J］.Cell Physiol Biochem, 2018, 46(5): 2165-2172.
［14］Do AR, Cho SJ, Cho YY, et al. Antiobesity effects of short-chain chitosan in diet-induced obese mice［J］. J Med Food, 2018, 21(9): 927-934.
［15］Mehlem A, Palombo I, Wang X, et al. PGC-1α coordinates mitochondrial respiratory capacity and muscular fatty acid uptake via regulation of VEGF-B［J］. Diabetes, 2016, 65(4): 861-873.
［16］Masuda I, Koike M, Nakashima S, et al. Apple procyanidins promote mitochondrial biogenesis and proteoglycan biosynthesis in chondrocytes［J］. Sci Rep, 2018, 8(1): 7229.
［17］Saihara K, Kamikubo R, Akagawa M, et al. Pyrroloquinoline quinone, a redox-active o-quinone, stimulates mitochondrial biogenesis by activating the SIRT1/PGC-1α signaling pathway［J］. Biochemistry, 2017, 56(50):6615-6625.
［18］Shokouhi S, Haghani K, Borji P, et al. Association between PGC-1alpha gene polymorphisms and type 2 diabetes risk: a case-control study of an Iranian population［J］.Can J Diabetes, 2015, 39(1): 65-72.
［19］Jemaa Z, Kallel A, Sleimi C, et al.The Gly482Ser polymorphism of the peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) is associated with type 2 diabetes in Tunisian population［J］. Diabetes Metab Syndr, 2015, 9(4): 316-319.
［20］邓德耀，袁文丽，金鑫鑫，等. PGC-1α基因GIy482Ser多态性与2型糖尿病的相关性研究［J］. 昆明医科大学学报，2014,35（3）：28-31.
［21］Park S, Kang S, Kim BC, et al. Interaction effect of PGC-1α rs10517030 variants and energy intake in the risk of type 2 diabetes in middle-aged adults［J］. Eur J Clin Nutr, 2017, 71(12): 1442-1448.
［22］孙亮，王松岚，孙宏，等. 北京地区汉族人群PPARGCIA基因启动子变异筛查及与2型糖尿病的关联研究［J］. 中华医学遗传学杂志，2014,31（3）：352-356.
［23］Yang Y, Mo X, Chen S, et al. Association of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PPARGC1A) gene polymorphisms and type 2 diabetes mellitus: a meta-analysis［J］. Diabetes Metab Res Rev, 2011, 27(2): 177-184.
［24］Song J, Liu YY, Long Y, et al. PPARGC1A gene Thr394Thr G/A polymorphism and its association with type 2 diabetes mellitus and insulin resistance in a Chinese population［J］. Zhonghua Yi Xue Yi Chuan Xue Za Zhi，2010, 27(5): 550-553.
［25］Zhu L, Huang Q, Xie Z, et al. PPARGC1A rs3736265 G>A polymorphism is associated with decreased risk of type 2 diabetes mellitus and fasting plasma glucose level［J］. Oncotarget, 2017, 8(23): 37308-37320.
［26］Vandenbeek R, Khan NP, Estall JL, et al.Linking Metabolic Disease With the PGC-1α Gly482Ser polymorphism［J］. Endocrinology, 2018, 159(2): 853-865.
［27］Weng SW, Lin TK, Wang PW, et al.Gly482Ser polymorphism in the peroxisome proliferator-activated receptor gamma coactivator-1alpha gene is associated with oxidative stress and abdominal obesity［J］. Metabolism, 2010, 59(4): 581-586.
［28］Vázquez-Del Mercado M, Guzmán-Ornelas MO, Corona Meraz FI, et al.The 482Ser of PPARGC1A and 12Pro of PPARG2 alleles are associated with reduction of metabolic risk factors even obesity in a mexican-mestizo population［J］. Biomed Res Int, 2015, 2015: 285491.
［29］Vimaleswaran KS, Radha V, Anjana M, et al.Effect of polymorphisms in the PPARGC1A gene on body fat in Asian Indians［J］. Int J Obes (Lond), 2006, 30(6): 884-891.
［30］Zamaninour N, Mirzaei K, Maghbooli Z, et al.Peroxisome proliferator-activated receptor gamma coactivator-1α variation: a closer look at obesity onset age and its related metabolic status and body composition［J］. Appl Physiol Nutr Metab, 2018,43(12):1321-1325.
［31］Petrovic MG, Kunej T, Peterlin B, et al.Gly482Ser polymorphism of the peroxisome proliferator-activated receptor-gamma coactivator-1 gene might be a risk factor for diabetic retinopathy in slovene population (Caucasians) with type 2 diabetes and the Pro12Ala polymorphism of the PPARgamma gene is not［J］. Diabetes Metab Res Rev, 2005, 21(5): 470-474.
［32］Gayathri SB, Radha V, Vimaleswaran KS, et al. Association of the PPARGC1A gene polymorphism with diabetic nephropathy in an Asian Indian population (CURES-41)［J］. Metab Syndr Relat Disord, 2010, 8(2): 119-126.
［33］李岑，杨驭媒. PGC-1α基因多态性与冠心病的相关性分析［J］. 医学检验与临床，2012,23（1）：7-9.
［34］张燕，徐伟伟，陈琪，等. 中国江苏地区汉族人群过氧化体增殖物激活型受体γ辅激活因子1α基因多态性与冠心病相关性［J］. 中国动脉硬化杂志，2007，7:546.
［35］Yongsakulchai P, Settasatian C, Settasatian N, et al.Association of combined genetic variations in PPARγ, PGC-1α, and LXRα with coronary artery disease and severity in Thai population［J］. Atherosclerosis, 2016, 248: 140-148.
［36］Lin YC, Chang PF, Chang MH, et al. A common variant in the peroxisome proliferator-activated receptor-γ coactivator-1α gene is associated with nonalcoholic fatty liver disease in obese children［J］. Am J Clin Nutr, 2013, 97(2): 326-331.
［37］Tai CM, Huang CK, Tu HP, et al. Interactions of a PPARGC1A variant and a PNPLA3 variant affect nonalcoholic steatohepatitis in severely obese taiwanese patients［J］. Medicine (Baltimore), 2016, 95(12): e3120.
［38］Yoneda M, Hotta K, Nozaki Y, et al.Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD)［J］. BMC Gastroenterol, 2008, 8:27.
［39］Shivaswamy V, Boerner B, Larsen J.Post-transplant diabetes mellitus: causes, treatment, and impact on outcomes［J］. Endocr Rev, 2016, 37(1): 37-61.
［40］Ouyang Meng, Xin Huawen, Tang Xia, et al. Ressearch on risk factors of adverse reactions caused by tacrolomus in renal transplant recipients［J］. Chinese pharmacist, 2016, 19(5):892-895.
［41］李彩霞，卢慧娟，徐建鸣，等. 肝移植术后代谢并发症危险因素及管理措施的研究进展［J］. 护理研究，2017,31（20）：2433-2436.
［42］Li Lu, Chen Huizhen, Liang Xingguang, et al. Research and treatment progress on post-transplantation diabetes mellitus caused by tacrolimus［J］. Chin J Transplant, 2017, 11(1):44-49.

[1]	李青华, 赵艳, 赵海港, 高朋飞, 徐炳欣. ABCB1 G2677T 基因多态性检测在缺血性脑卒中患者应用阿托伐他汀降脂治疗中的价值[J]. 中国临床药理学与治疗学, 2023, 28(6): 633-640.
[2]	朱丽, 魏兵, 廖世峨, 张超, 郑晓宇, 刘亚军. 药物代谢酶细胞色素P450单核苷酸多态性影响哮喘儿童吸入皮质醇激素疗效研究[J]. 中国临床药理学与治疗学, 2023, 28(5): 536-543.
[3]	张志英, 靳秀红, 张小宁, 张向峰, 罗青林, 张松林. TBX21和ADCY9多态性在儿童哮喘发生发展中的临床研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 407-412.
[4]	刘璐, 石雨菲, 何庆烽, 徐凤艳, 王鲲, 蔡卫民, 相小强. 群体模型分析方法评估基因多态性对药物PK/PD的影响[J]. 中国临床药理学与治疗学, 2023, 28(11): 1275-1282.
[5]	王爽, 刘嘉, 张月丽. POR*28基因多态性与中国肾移植患者他克莫司稳定剂量的相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(9): 991-997.
[6]	付虹, 田磊. 缺血性脑卒中伴高血压病患者个体化精准治疗的研究[J]. 中国临床药理学与治疗学, 2022, 27(8): 870-876.
[7]	陈文刚, 殷勤, 张巍巍, 周露露, 寇婉青, 袁小龙. 皖南地区高血压患者MTHFR基因多态性分布及与血Hcy相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(7): 768-774.
[8]	武元竹, 刘俊, 杨魁, 彭静, 栾家杰, 韦俊, 张大发, 宋帅, 袁小龙, 王中方, 张年宝, 解丹, 姜鹏, 范洁. 安徽地区汉族人群CYP2C9*3和VKORC1-1639G>A基因多态性分布及对华法林稳定剂量的影响[J]. 中国临床药理学与治疗学, 2022, 27(6): 652-659.
[9]	陈佳音, 王丽, 王立军, 童刚领, 马洁, 陈西敬, 卢杨. 有机阳离子转运体基因多态性与奥沙利铂毒性及疗效的相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(2): 171-177.
[10]	周敏敏, 余露, 韩超, 顾达民, 雷道赟. 人类胆固醇酯转移蛋白rs5882基因多态性与围术期神经认知功能紊乱的相关性[J]. 中国临床药理学与治疗学, 2021, 26(7): 768-774.
[11]	王春玲, 周仁精, 冯瑞, 吴燕能. 脂联素45 T/G基因多态性对利拉鲁肽治疗2型糖尿病患者的临床疗效[J]. 中国临床药理学与治疗学, 2021, 26(3): 312-317.
[12]	李静, 马丽娟, 袁圆, 王捷, 郁长治, 赵军. 吸入性糖皮质激素布地奈德相关基因多态性与哮喘疗效的关系[J]. 中国临床药理学与治疗学, 2021, 26(11): 1250-1258.
[13]	杨春艳, 张文, 王培培, 彭静, 江佳, 宋静, 刘俊, 李越然, 杨魁, 汪盛, 徐振宇, 栾家杰. 叶酸代谢通路相关基因多态性对血清同型半胱氨酸浓度的影响[J]. 中国临床药理学与治疗学, 2021, 26(11): 1259-1264.
[14]	梅笛, 沈纪中, 刘春妍, 陆程灿, 徐伟, 彭宇竹. 新型口服抗凝药的药物基因组学研究进展[J]. 中国临床药理学与治疗学, 2021, 26(10): 1200-1207.
[15]	王凤玲, 孟祥云, 陈正徐, 曹荣娟, 何争民, 叶茜, 王聪, 李琪. 安徽地区汉族心血管疾病患者SLCO1B1与ApoE基因多态性分布及其在他汀类药物临床个体化应用中的意义[J]. 中国临床药理学与治疗学, 2021, 26(1): 40-48.

PGC-1α基因多态性与代谢性疾病的相关性

Correlation between PGC-1α gene polymorphism and metabolic diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价